DxPG80 HOW-TO GUIDE (FRANCE)

Human circulating Progastrin (hPG80) Immunoassay

  1. The DxPG80 Elisa test

  2. DxPG80 IVD test how-to guide

    • Prescription​

Last updated: August 3, 2020

Access to this page is restricted to healthcare professionals only

The DxPG80 test is an ELISA (Enzyme-Linked Immunosorbent Assay) for the detection of hPG80 (circulating human progastrin).

 

The test is intended for professional laboratory use only.

Please note that for greater clarity, we use the name hPG80, referring to extracellular Progastrin.

The test is based on the principle of a sandwich ELISA to measure the concentration of hPG80 in plasma samples that have been collected in EDTA tubes.  

 

Briefly, a capture antibody specific for hPG80 is immobilised on the 96-well plate. The hPG80 present in the calibrators and samples added to the wells will bind to the immobilized capture antibody. The test plate includes calibrators which are used to estimate the level of hPG80 in EDTA plasma samples. The wells are washed and an anti-hPG80 detection antibody coupled to horseradish peroxidase (HRP) is added, resulting in an antibody-antigen-antibody complex. After a second wash, a substrate solution of 3,3',5,5'-Tetramethylbenzidine (TMB) is added to the wells, producing a blue colour directly proportional to the amount of hPG80 present in the initial sample. The Stop Solution changes the colour from blue to yellow, and the wells are read at 450 nm with a microplate reader.

 

The assay is technically characterised in manual mode by a limit of detection (LOD, 1 pM) and a limit of quantification (LOQ, 3.3 pM). The LOD detects the presence of hPG80 and the LOQ gives the concentration at which the assay is quantitative.

Table 1 : Comparative description of hPG80 in Controls (healthy blood donors 18-40 years old at low risk of cancer) and Cancer patients (16 cancers tested, all combined)[1]. Reference range are given for a 2.5 (low range) and 97.5 (high range) percentile. IQR: Inter-Quartil Range, 25-75%. SE: Standard Error.

BIBLIOGRAPHY

[1]. You et al, EBioMedicine, 2020 Jan;51:102574

From the blood test to reporting the result to the physician:

IT'S TIME TO CONTROL CANCER

It has been shown that hPG80 (Circulating Progastrin) is produced by all cancer cells across all stages, but in quantities 100 to 1000 times higher by cancer stem cells which are considered to be primarily responsible for recurrence and metastasis. 

hPG80 is released from the tumor and becomes detectable in the blood, making hPG80 the only blood biomarker that not only detects the presence but also the activity of the tumor.

16 different cancers have been tested, the 16 were positive. Of these 16 cancers, 11 have been published to date.

Detection and assay of hPG80 can provide Physicians with new information that can help them:

  • Evaluate treatment efficacy,

  • Monitor risk of relapse,

  • Assess Minimal Residual Disease (MRD) risk,

  • Diagnose cancers which have no biomarker and for at-risk populations, in order to detect early enough the tumor, easily located in these populations.

ECS-Progastrin is a subsidiary of Progastrine Invest SCSp (Cancer Control Funding Fund)  11 côte d'Eich, L1450, Luxemburg City - Grand Duchy of Luxemburg

MAINS LOCATIONS AND OFFICES:

  • LUXEMBURG

  • SWITZERLAND

  • FRANCE

  • UNITED ARAB EMIRATES

  • UNITED STATES OF AMERICA

MAINS COMPANIES:

  • ECS PROGASTRIN

  • ECS PROGASTRIN LAB

  • PROGASTRINE ET CANCERS

  • EUROBIODEV

  • PROGASTRIN MANUFACTURING

Progastrine Invest SCSp and its subsidiaries:

  • focus on innovation in cancer diagnosis, localization, follow-up and treatment,

  • hold the rights to the first hPG80 (Circulating Progastrin) assay which is now available,

  • hold the rights to the cancer therapy project with an anti-hPG80 antibody.

 

For ethical reasons and out of respect for practitioners, health institutions, populations and regulations in force in all countries where they operate, Progastrine Invest SCSp and its subsidiaries pay extreme attention to the information they publicly provide.

 

The management of Progastrine Invest SCSp subsidiaries and their scientific committee would like to remind you that only information published on the official communication media of the group's companies can be considered as confirmed and authorised.

© 2015-2020 ECS-Progastrin ® . All rights reserved